Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Viral Recombination00:57

Viral Recombination

Cells are sometimes infected by more than one virus at once. When two viruses disassemble to expose their genomes for replication in the same cell, similar regions of their genomes can pair together and exchange sequences in a process called recombination. Alternatively, viruses with segmented genomes can swap segments in a process called reassortment.
Diversity of Antigen Receptors01:28

Diversity of Antigen Receptors

Antigen receptors are essential components of the immune system crucial in defending the body against foreign invaders. These receptors are present on the surface of B and T cells, enabling them to recognize antigens and mount an appropriate immune response.
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
Viral Mutations00:36

Viral Mutations

A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material for adaptive...
Retroviruses02:33

Retroviruses

Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
Homologous Recombination02:31

Homologous Recombination

The basic reaction of homologous recombination (HR) involves two chromatids that contain DNA sequences sharing a significant stretch of identity. One of these sequences uses a strand from another as a template to synthesize DNA in an enzyme-catalyzed reaction. The final product is a novel amalgamation of the two substrates. To ensure an accurate recombination of sequences, HR is restricted to the S and G2 phases of the cell cycle. At these stages, the DNA has been replicated already and the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Entering HIV Medical Care With AIDS in the Era of Immediate Access to Antiretroviral Treatment.

Journal of acquired immune deficiency syndromes (1999)·2025
Same author

Hospital antimicrobial stewardship: profiling the oral microbiome after exposure to COVID-19 and antibiotics.

Frontiers in microbiology·2024
Same author

HIV Promotes Atherosclerosis via Circulating Extracellular Vesicle MicroRNAs.

International journal of molecular sciences·2023
Same author

Early Antiretroviral Therapy Not Associated With Higher Cryptococcal Meningitis Mortality in People With Human Immunodeficiency Virus in High-Income Countries: An International Collaborative Cohort Study.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2023
Same author

Associations between alcohol and cigarette use and type 1 and 2 myocardial infarction among people with HIV.

HIV medicine·2023
Same author

Selection of cognitive impairment screening tools for longitudinal implementation in an HIV clinical care setting.

AIDS care·2023
Same journal

Identification of a Complex HIV-1 Circulating Recombinant Form (CRF203_cpx) Originating from Three Main Circulating Recombinant Forms in China.

AIDS research and human retroviruses·2026
Same journal

Near Full-Length Genome Characterization of a Novel Second-Generation HIV-1 CRF01_AE/CRF07_BC Recombinant Identified in an MSM Individual in Guizhou, China.

AIDS research and human retroviruses·2026
Same journal

Evolving Indications and Diagnostic Spectrum of Bone Marrow Examination in People with HIV During the Antiretroviral Therapy Era: A 6-Year Retrospective Study.

AIDS research and human retroviruses·2026
Same journal

A Conserved Natural Killer Cell Transcriptional Fingerprint in Rhesus Macaque Models of Acute Viral Infections.

AIDS research and human retroviruses·2026
Same journal

Perceived Ethical Risks of HIV Phylogenetic Research: Insights from Professional Stakeholders in Uganda.

AIDS research and human retroviruses·2026
Same journal

Genomic Characterization of Two Novel Human Immunodeficiency Virus-1 Recombinant Forms (CRF01_AE and B) in Men Who Have Sex with Men in Hebei, China.

AIDS research and human retroviruses·2026
See all related articles

Related Experiment Video

Updated: Jun 8, 2026

A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses
14:23

A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses

Published on: August 31, 2014

HIV-1 diversity after a class switch failure.

Michael A Kolber1, Patricia Buendia, Victor Degruttola

  • 1Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida 33136, USA. mkolber@med.Miami.edu

AIDS Research and Human Retroviruses
|September 22, 2010
PubMed
Summary
This summary is machine-generated.

The order of initial highly active antiretroviral therapy (HAART) regimens, whether protease inhibitor (PI)-based or efavirenz (EFV)-based, influences HIV genetic diversity after subsequent treatment failures. Switching from PI to EFV regimens results in greater viral diversity.

More Related Videos

Amplification of Near Full-length HIV-1 Proviruses for Next-Generation Sequencing
10:18

Amplification of Near Full-length HIV-1 Proviruses for Next-Generation Sequencing

Published on: October 16, 2018

Amplifying and Quantifying HIV-1 RNA in HIV Infected Individuals with Viral Loads Below the Limit of Detection by Standard Clinical Assays
13:58

Amplifying and Quantifying HIV-1 RNA in HIV Infected Individuals with Viral Loads Below the Limit of Detection by Standard Clinical Assays

Published on: September 26, 2011

Related Experiment Videos

Last Updated: Jun 8, 2026

A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses
14:23

A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses

Published on: August 31, 2014

Amplification of Near Full-length HIV-1 Proviruses for Next-Generation Sequencing
10:18

Amplification of Near Full-length HIV-1 Proviruses for Next-Generation Sequencing

Published on: October 16, 2018

Amplifying and Quantifying HIV-1 RNA in HIV Infected Individuals with Viral Loads Below the Limit of Detection by Standard Clinical Assays
13:58

Amplifying and Quantifying HIV-1 RNA in HIV Infected Individuals with Viral Loads Below the Limit of Detection by Standard Clinical Assays

Published on: September 26, 2011

Area of Science:

  • Virology
  • Immunology
  • Genetics

Background:

  • Highly active antiretroviral therapy (HAART) has transformed HIV management.
  • Sequential HAART failures can lead to the accumulation of drug resistance mutations.
  • Understanding viral diversity post-failure is crucial for optimizing treatment strategies.

Purpose of the Study:

  • To investigate if the initial choice of a protease inhibitor (PI)-based or efavirenz (EFV)-based HAART regimen affects HIV genetic diversity after a second, class-switch salvage regimen failure.
  • To compare the persistence of drug resistance mutations between different sequential HAART regimen orders.

Main Methods:

  • Retrospective analysis of sequential HAART failures in HIV-1 infected individuals.
  • Genotyping to identify drug resistance mutations at each failure point.
  • Phylogenetic tree construction and branch length analysis to assess viral diversity.

Main Results:

  • In the EFV-to-PI (EP) group, 10/12 cases retained key non-nucleoside reverse transcriptase inhibitor (NNRTI) mutations at second failure, versus 5/13 in the PI-to-EFV (PE) group (p=0.041).
  • Phylogenetic analysis revealed greater viral diversity in the PE group compared to the EP group.
  • This suggests that in the PE group, second-failure mutations accumulated on a virus closer to the baseline, rather than the first-failure dominant strain.

Conclusions:

  • The sequence of initial HAART regimens significantly impacts HIV viral diversity following multiple treatment failures.
  • Starting with a PI-based regimen followed by an EFV-based regimen (PE sequence) may lead to increased viral diversity compared to the opposite sequence (EP).
  • This finding has implications for predicting treatment outcomes and managing drug resistance in patients with sequential HAART failures.